IMMUNOTEC MEDICAL CORP. ANNOUNCES CLINICAL DEVELOPMENT PROGRAM
The attached release announces the launch of an important clinical trial in
the field of cancer/cachexia. The trial will take place at three highly
regarded cancer institutes in Canada; the Principal investigator of the
study is an authority in the field of cachexia and palliative care in
cancer.
Much of what we learn from this trial will be applied to our product
development work on Immunocal/HMS 90 with the objective of further
augmenting the product's potency.
John Molson
Vice-President, Research & Development

http://www.immunotec.com/files/Immunotec/aimm1207_E.pdf

I would like to take this opportunity to address some issues contained in
postings concerning Immunocal.

In regards to questions on clinical efficacy I refer you to the Pubmed site
where both Dr Bounous and Dr Baruchel have had their work on Immunocal
published - approx 80 articles.

Immunotec recently completed a trial with the Canadian HIV network - double
blind randomized w/ placebo & drug.

The catalyst for the said trial was a study conducted by Dr Sylvain Baruchel
on 11 children with AIDS and Wasting - as you are aware all 11 children put
on weight.

Dr Larry Lands - Associate Prof Pediatrics McGill University in Montreal
recently completed a study on Immunocal & healthy adults - part of a two arm
study in Pulmonary Obstruction - the said paper will be presented at the
American Lung Association meeting in San Diego April 99.

As a note of interest it was one of 30 culled from 5000 submitted to be
presented to the media for its novelty.

So that you are aware what I have mentioned is only a small component of
what we have initiated in terms of furthering our research.

Immunotec has been granted 6 method of use patents - two of which
are specifically for treatment of Cancer & AIDS.

With regard to Immunotec's distribution system we use three methods:

1) Immunocare, which is direct to the consumer
2) Networking
3) Classic Distribution -  Drug stores etc - this accommodates the recent
  granting of insurance reimbursement in the United States.

You mentioned the issue of FDA approval, you are no doubt aware that the FDA
regulates the supplement category (it does not approve supplements) as such
it is neither useful or feasible to get an approval for Immunocal as we are
classed as a supplement.

The FDA action concerning importation was the result unauthorized claims
made on certain websites, this has since been remedied.

I hope this answers some of the queries put forth in your posting.

Kind regards

John H Molson
Vice President - Research & Dev
Immunotec Research

Yes there is a disclaimer on the Immunotec site regarding what the product
will or won't do. This is because it is classified as a food.
As a prescription drug it would have much more expensive.
It is drug qualified.
Aren't you tired of side effect drugs?
Something natural and a food that treats, prevents, inhibits cancer, aids in
chemo and radio therapies with medical cancer patents is refreshing.
You can order a copy of the cancer patent from their price list.
Or follow the international medical patent links to read them.
http://www.immunotec.com/page.asp?intNodeID=4809